The National Institute for Health and Care Excellence

NICE announces Professor Jonathan Benger CBE as new chief executive

NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
National Institute for Health and Care Excellence

Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...
National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Lifileucel for previously treated unresectable or metastatic melanoma ID3863 Draft guidance Technology appraisal guidance 22 January 2026 Filgotinib for treating axial spondyloarthritis ID6594 ...
National Institute for Health and Care Excellence

Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...
National Institute for Health and Care Excellence

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for talquetamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Topic prioritisation

Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290] Medicines evaluation Not selected 12 December 2025 Cyclosporin eye drops for treating ...